section name header

Indications ⬇

High Alert

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: peripheral edema

Derm: pruritus, rash

EENT: abnormal vision, diplopia

Endo: adrenal hypercorticism

GI: nausea, vomiting, abdominal pain, anorexia, constipation, diarrhea, dysphagia, HEPATOTOXICITY

GU: breast pain (women)

Hemat: neutropenia, thrombocytopenia, anemia

Local: injection site reactions, pain at injection site

Metab: ↑weight

MS: back pain, myalgia

Neuro: fatigue, headache, abnormal coordination, abnormal gait, anxiety, depression, dizziness, drowsiness, hemiparesis, mental status changes, SEIZURES, weakness

Resp: cough

Misc: fever, SECONDARY MALIGNANCY

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Newly Diagnosed Anaplastic Astrocytoma

Refractory Anaplastic Astrocytoma

Glioblastoma Multiforme

US Brand Names ⬆ ⬇

Temodar

Action ⬆ ⬇

  • Temozolomide is not active until converted at physiologic pH to MTIC, which alkylates DNA, disrupting its synthesis.
Therapeutic effects:
  • Death of rapidly replicating cells, especially malignant ones, resulting in regression or slowed tumor growth.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: alkylating agents

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly converted to MTIC, the active metabolite.

Distribution: Unknown.

Metabolism/Excretion: Further metabolism results in the formation of methylhydrazine, which is responsible for most activity.

Half-Life: 1.8 hr.

Canadian Brand Names ⬆ ⬇

Temodal

Time/Action Profile ⬆ ⬇

(effect on blood counts)

ROUTEONSETPEAKDURATION
PO/IV (WBC)unknown28 days (range 1–44 days)14 days
PO/IV (platelets)unknown26 days (range 21–40 days)14 days

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

te-mo-ZOLE-oh-mide

Code ⬆

NDC Code